Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, pharmacokinetics, pharmacodynamics, and early effects of the drug combination ZE50-0134 and Azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia AML. This open-label Phase 1b study focuses on patients who have not responded to previous treatments or whose disease has returned. The study aims to find the best dose and schedule of this combination therapy using a 3 3 dose escalation design before expanding to a larger group of patients. The study has two parts first, a dose escalation phase where different doses of Lonitoclax ZE50-0134 combined with Azacitidine are tested to find the biologically effective dose. Then, an expansion phase will enroll about 30 patients divided into two groups receiving different dose levels to determine the recommended phase 2 dose. Treatments include oral capsules of ZE50-0134 given once or twice daily and Azacitidine administered at 75 mgm2 daily for 7 days. Adjustments to doses may occur based on tolerability and safety findings. Participants will be involved in up to 24 cycles of treatment, each lasting 4 weeks. They will undergo assessments including safety monitoring and measuring responses to treatment. Researchers will evaluate how well patients blood counts recover, monitor side effects, and track event-free survival and remission duration. Close monitoring during treatment helps understand the best dosing and safety profile of the combination. The total study duration may extend up to nearly two years, including follow-up periods.
Actively Recruiting
Researchers are evaluating the recombinant non-immunogenic staphylokinase in patients who have suffered an acute ischemic stroke within 4.5 to 24 hours after symptom onset. This phase III, multicenter, double-blind, randomized, placebo-controlled trial focuses on patients with large vessel occlusion in the anterior circulation and salvageable brain tissue. The study aims to determine if this treatment is effective and safe when given beyond the currently recommended 4.5-hour window for intravenous thrombolysis. Participants will be randomly assigned to receive either a single intravenous bolus of 10 mg non-immunogenic staphylokinase or a placebo injection immediately after randomization. The bolus is administered rapidly within 5 to 10 seconds and is not adjusted by body weight. Patients intended for direct thrombectomy are excluded. The study includes a follow-up period of 90 days to assess outcomes. During the trial, participants will undergo neuroimaging assessments such as CT or MRI to confirm eligibility and monitor brain perfusion. Researchers will measure functional outcomes using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days. They will also monitor reperfusion rates, mortality, and any adverse events. This comprehensive evaluation will help assess the treatments impact on restoring blood flow and improving recovery after stroke.